logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs' Unit To Acquire Royalties For Bystolic From Janssen Pharmaceutica

Forest Laboratories Inc (FRX) Monday revealed that its wholly-owned subsidiary unit, Forest Laboratories Holdings Limited, has entered into a definitive agreement with Janssen Pharmaceutica NV, wherein the subsidiary unit will acquire all U.S. patents and other U.S. and Canadian intellectual property for Bystolic (nebivolol), which is currently approved in the United States for the treatment of hypertension.

FRX revealed that its subsidiary unit has agreed to make a one-time cash payment of $357 million to Janssen Pharmaceutica NV, and, in turn, Janssen Pharmaceutica will assign all U.S. patents and other U.S. and Canadian know-how covering Bystolic, including the nebivolol composition of matter patent in the U.S. to the subsidiary unit of FRX.

The company further revealed that the subsidiary unit will amortize the one-time cash payment over the remaining patent life of Bystolic.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Following the sell-off seen in the previous session, stocks showed a strong move back to the upside during trading on Wednesday. The markets benefited from a positive reaction to the latest batch of economic news. Frontier Airlines has crashed its own website after offering $1 fares from select U.S. markets. In another sign that the jobs market is improving, the Federal Reserve's Beige Book has reported increased wage pressures in a number of districts around the U.S. "Several" of the 12 district banks "reported increasing wage pressures caused by labor market tightening," according to the Beige Book,...
comments powered by Disqus
Follow RTT